一种治疗性小分子增强了g-振荡,并改善了阿尔茨海默病模型小鼠的认知/记忆
bioRxiv : the preprint server for biology
|December 18, 2023
概括
一种新药,DLL-920,增强了马振荡,并改善了阿尔茨海默氏症患者的记忆力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 认知科学 认知科学
背景情况:
- 马振荡 (30-120 Hz) 对认知过程和工作记忆至关重要.
- 在像阿尔茨海默氏症 (AD) 这样的神经系统疾病中观察到较低的马振荡.
- 现有的阿尔茨海默病治疗方法在治疗认知衰退方面往往缺乏有效性.
研究的目的:
- 确定和开发用于阿尔茨海默病的新疗法.
- 为了研究调节马振荡以提高认知能力的潜力.
- 探索一种新的中枢神经系统 (CNS) 药物疗法类别,针对特定的GABA受体.
主要方法:
- 开发一种可以穿透大脑的小分子,DLL-920.20.
- 利用解剖学和药理学方法来识别目标受体.
- 在阿尔茨海默病的小鼠模型中测试了DDL-920.
主要成果:
- DDL-920有效地增加了大脑中的马振荡.
- 该药物在AD小鼠模型中显著改善了认知和记忆.
- DDL-920作为α1β2δGABA受体的选择性负调节器 (NAM) 起作用.
结论:
- DDL-920显示为阿尔茨海默病的新型治疗药物具有前途.
- 该药物通过放大内源性马振荡来增强认知表现.
- 这种方法代表了一种独特的,依赖于状态的方法来改善认知功能.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


